https://pharminent.com/fda-approves-ultragenyx-gene-therapy-fayuvi-for-sanfilippo-syndrome-type-a/ 2026-09-18T16:37:16Z Pharminent en FDA approves Ultragenyx gene therapy Fayuvi for Sanfilippo syndrome type A 2026-09-18T15:48:40Z Blog https://pharminent.com/subscribe-free/ 2026-09-18T15:32:25Z Pharminent en Subscribe 2026-09-18T11:32:52Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-17-2026/ 2026-09-17T20:12:45Z Pharminent en Strategic News Watch • September 17, 2026 2026-09-17T20:12:43Z Blog https://pharminent.com/nice-clears-enhertu-in-her2-low-breast-cancer-after-england-raised-its-cost-effectiveness-threshold/ 2026-09-17T19:47:23Z Pharminent en NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold 2026-09-17T19:47:20Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-september-16-2026/ 2026-09-17T15:20:32Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • September 16, 2026 2026-09-17T15:20:29Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-september-16-2026/ 2026-09-17T14:55:08Z Pharminent en Manufacturing Intelligence • Weekly Digest • September 16, 2026 2026-09-17T14:55:05Z Blog https://pharminent.com/novartis-drops-als-for-lifonebart-after-astrals-misses-every-endpoint-but-keeps-the-molecule-in-alzheimers/ 2026-09-16T20:11:34Z Pharminent en Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer's 2026-09-16T19:51:38Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-15-2026/ 2026-09-16T17:50:05Z Pharminent en Oncology Intelligence Digest • September 15, 2026 2026-09-16T17:49:59Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-16-2026/ 2026-09-16T17:43:55Z Pharminent en Strategic News Watch • September 16, 2026 2026-09-16T17:43:51Z Blog